Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.

Benelli, Matteo; Colleoni, Marco; De Laurentiis, Michelino; Bianchini, Giampaolo; Zamagni, Claudio; Del Mastro, Lucia; Callari, Maurizio; Guarneri, Valentina; Arpino, Grazia; Puglisi, Fabio; Paris, Ida; Malorni, Luca; Caputo, Roberta; Bianchi, Giulia; Tamberi, Stefano; Zambelli, Alberto; Cazzaniga, Marina E; Valsecchi, Diletta; Montemurro, Filippo; Allegrini, Giacomo; Orditura, Michele; Adamo, Vincenzo; Romagnoli, Emanuela; Valerio, Maria Rosaria; Cinieri, Saverio; Castelletti, Daniela; Grasso, Donatella; Fenderico, Nicola

doi:10.1158/1078-0432.CCR-25-0650

Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.

2026-06-15, Clinical Cancer Research (10.1158/1078-0432.CCR-25-0650) (online)
Matteo Benelli, Marco Colleoni, Michelino De Laurentiis, Giampaolo Bianchini, Claudio Zamagni, Lucia Del Mastro, Maurizio Callari, Valentina Guarneri, Grazia Arpino, Fabio Puglisi, Ida Paris, Luca Malorni, Roberta Caputo, Giulia Bianchi, Stefano Tamberi, Alberto Zambelli, Marina E Cazzaniga, Diletta Valsecchi, Filippo Montemurro, Giacomo Allegrini, Michele Orditura, Vincenzo Adamo, Emanuela Romagnoli, Maria Rosaria Valerio, Saverio Cinieri, Daniela Castelletti, Donatella Grasso, and Nicola Fenderico (?)

This phase IIIb study prospectively evaluated the prognostic and predictive value of baseline and dynamic circulating tumor DNA (ctDNA) in postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with first-line ribociclib/letrozole.

This article has not yet been included in any curations.

Comments

There are no comments on this article yet.

You need to login or register to comment.

BioSothis

Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.